BMY vs PATH · P/E 17, rev $48.19B vs P/E 19, rev $1.61B
Bristol-Myers Squibb Company (BMY) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Bristol-Myers Squibb Company (BMY) is a drug manufacturers - general company listed on US. It is led by Chris Boerner.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported BMY revenue for 2025-12-31 was $48.19B. Net income was $7.05B. Revenue was down 0.2% from 2024-12-31 to 2025-12-31. BMY currently screens at market cap $95.36B and trailing P/E 17.5.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
BMY currently screens at market cap $95.36B and trailing P/E 17.5. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the BMY and PATH stock pages for the full models.
Not investment advice.